NCT03518606 - Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

December 19, 2024

Conditions

Advanced Solid TumoursBreast CancerHead and Neck CancerCervix CancerProstate Cancer

Interventions

DRUG

Durvalumab + Tremelimumab + metronomic Vinorelbine

Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy

Trial Locations (9)

Institut Paoli-Calmettes, Marseille

Centre Georges-François Leclerc, Dijon

Centre Eugène Marquis, Rennes

Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers

Centre François Baclesse, Caen

Centre Antoine Lacassagne, Nice

Institut Curie, Paris

Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain

Gustave Roussy, Villejuif